Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain;Análisis de la relación coste-efectividad a corto y largo plazo de clopidogrel añadido a terapia estándar en pacientes con síndrome coronario agudo en España

Revista Espanola de Cardiologia

Volumn 58, Issue 12, 2005, Pages 1385-1395

  Badia, Xavier ^a   Bueno, Héctor ^b   González Juanatey, José R ^c   Valentín, Vicent ^d   Rubio, Marta ^a  

^a Health Outcomes Research Europe   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Acute coronary syndrome; Clopidogrel; Cost effectiveness

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INTERNATIONAL COOPERATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; OUTCOMES RESEARCH; PROBABILITY; SENSITIVITY ANALYSIS; SPAIN; STANDARDIZATION;

EID: 32044451059     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(05)74068-9     Document Type: Article

References (37)

1. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999;33:634-9.
2. Valentin V. Clopidogrel en el síndrome coronario agudo sin ascenso del segmento SR. Repercusiones clínicas del estudio CURE. Rev Esp Cardiol. 2001;54:1127-34.
3. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001;134:224-38.
4. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost. 1999;82:997-1004.
5. Mehta SR. ACC/AHA. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines. J Invasive Cardiol. 2002;14:Suppl E:27-35.
6. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
7. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-5.
8. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100: 2045-8.
9. Escolar G, Heras M. Clopidogrel, a selective inhibitor of platelet ADP receptors. Drugs Today (Barc). 2000;36:187-99.
10. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80:512-8.
11. Budaj A, Yusuf S, Mehta S, Fox K, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-6.
12. Sacristán JA, Ortún V, Rovira J, Prieto L, García-Alonso F. La evaluación económica en medicina. Med Clin (Barc). 2004;122: 379-82.
13. Prieto L, Sacristán JA, Pinto JL, Badia X, Antoñanzas F, Del Llano J. El análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. Med Clin (Barc). 2004;122; 423-9.
14. Prieto L, Sacristán JA, Antoñanzas F, Rubio-Terrés C, Pinto JL, Rovira J. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Med Clin (Barc). 2004;122: 505-10.
15. Canadian Coordinating office for health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA; 1998. p. 11-49.
16. Canadian Coordinating office for health Technology Assessment. A Guidance document for the costing process: version 1.0. Ottawa: CCOHTA; 1996. p. 2-4.
17. Lamy A, Jönsson B, Weintraub W, Zhao F, Chrolavicius S, Bakhai A, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil. 2004;11:460-5.
18. Lindgren P, Jönsson B. Modelling the cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Sweden (abstract). J Am Coll Cardiol. 2003;41 Suppl 2:450.
19. Lindgren P, Jonssön B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Inter Med. 2004;255:562-70.
20. The Centre for Epidemiology. The Swedish Hospital Discharge Register. Stockholm: The National Board of Health and Welfare, 1999. Disponible en: http://www.sos.se/epc/english/ParEng.htm
21. The Centre for Epidemiology. The Cause of Death Register. 2001. Stockholm: The National Board of Health and Welfare, 2001. Disponible en: http://www.sos.se/epc/english/dorseng.htm
22. Arós F, Cuñat J, Loma-Osorio A, Torrado E, Bosch X, Rodríguez JJ, et al. Tratamiento del infarto agudo de miocardio en España en el año 2000. El estudio PRIAMHO II. Rev Esp Cardiol. 2003;56:1165-73.
23. Bueno H, Bardají A, Fernández-Ortiz A, Marrugat J, Martí H, Heras M. Manejo del síndrome coronario agudo sin elevación de ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal Español). Rev Esp Cardiol. 2005;58:244-52.
24. Base de datos de costes sanitarios SOIKOS [CD-ROM]. Barcelona: Centro de estudios en Economía de la Salud y Política Social; 2004.
25. CGCOF: Base de datos de Medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos. Disponible en: www.portal-farma.com
26. Gravelle H, Smith D. Discounting for Health Effects in Cost-Benefit and Cost-Effectiveness Analysis. J Health Econ. 2001;10: 587-99.
27. Evans C, Crawford E. Expert judgment in pharmacoeconomic studies. Guidance and future use. Pharmacoeconomics. 2000;17: 545-53.
28. Lindgren P, Jönsson B, Spiesser J, Carita P, Gabriel S. Short and long-term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-Segment elevation in Scandinavian countries (abstract). Value in Health. 2003;6:621.
29. Van Hout BA, Tangelder MJD, Bervoets P, Gabriel S. Cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands (abstract). Value in Health. 2003;6:667.
30. Annemans L, Lindgren P, Frei A, Gabriel S, Carita P. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis (abstract). Eur Heart J. 2003;24:586.
31. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334-43.
32. Plans P, Rovira J. Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes. Med Clin (Barc). 1995;105: 327-33.
33. Plans-Rubio P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care. 1998;14: 320-30.
34. Hart WM, Rubio-Terrés C, Fernández M, González Juanatey JR. Análisis coste-efectividad del tratamiento con ramipril de pacientes con alto riesgo de padecer eventos cardiovasculares en España. An Med Interna. 2002; 19:515-20.
35. Antoñanzas F, Antón F. Evaluación económica de eptifibatide. Rev Esp Cardiol. 2001;54:169-74.
36. Latour-Pérez J, Navarro-Ruiz A, Ridao-López M, Cervera-Montes M. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value in Health. 2004;7:52-60.
37. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk. 1994; 1:333-9.